Search Results
Your search for ,New matches 16922 pages
Showing 151 - 200Refractory LBCL: CD19-Targeting CAR T-Cell Therapy Plus Rituximab
A dual-antigen targeting combination of the CD19-targeting chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel plus the CD20-targeting agent rituximab led to durable responses and reduced relapses in patients with refractory large B-cell lymphoma (LBCL), according to findings...
Researchers Create Immune Cell Atlas of Bone Marrow in Patients With Multiple Myeloma
Scientists at several institutions across the country, in partnership with the Multiple Myeloma Research Foundation (MMRF), have helped generate the largest single-cell immune cell atlas of the bone marrow in patients with multiple myeloma. The findings, published by Pilcher et al in Nature Cancer, ...
Small Study Examines Potential of Artificial Saliva in Patients With Head and Neck Cancer
An artificial saliva in the form of a mouthwash, produced with a protein extracted from sugarcane and modified in a laboratory, may aid in treating hyposalivation among patients with head and neck cancer, a new study has found. Radiotherapy delivered very close to the mouth can destroy salivary...
Are Food Preservatives Linked to Increased Cancer Risk?
Higher intake of food preservatives, widely used in industrially processed foods and beverages to extend shelf life, is associated with a modestly increased risk of cancer, according to the results of a French study published by Hasenböhler et al in The BMJ. While further research is needed to...
Investigational PSMA-Targeted Radioligand Reduced Off-Target Uptake in Prostate Cancer Models
A novel prostate-specific membrane antigen (PSMA)-targeted radioligand therapy shows the potential to enhance therapeutic effects for patients with PSMA-positive prostate cancer while eliminating the potential for severe adverse effects such as xerostomia, according to preclinical findings...
Benefit of Azacitidine Plus Venetoclax Confirmed in AML
The combination of the hypomethylating agent azacitidine and the BCL2 inhibitor venetoclax is an established regimen in older, unfit patients with acute myeloid leukemia (AML). Now, a phase II randomized trial indicates potential for less intensive therapy in the newly diagnosed fit population. In...
ACS Guidelines for Cervical Cancer
Self-collection of vaginal samples for human papillomavirus (HPV) testing is now being considered an acceptable, recommended option for cervical cancer screening, per recent updates to the American Cancer Society’s (ACS) guidelines published in CA: A Cancer Journal for Clinicians. Another...
Using AI to Ensure That All Patients With Cancer Have Access to Precision Oncology Care
Steve Brown, Founder and Chief Executive Officer of CureWise (curewise.com), an artificial intelligence (AI)-driven patient advocacy app, describes his year-long quest to understand a series of symptoms that ultimately led to a diagnosis of light chain (AL) amyloidosis—a disease closely related to ...
Addition of Epcoritamab to Lenalidomide Plus Rituximab in Relapsed or Refractory Follicular Lymphoma
As reported in The Lancet by Falchi et al, an interim analysis of the phase III EPCORE FL-1 trial has shown that the addition of the bispecific antibody epcoritamab (for B-cell CD20 and T-cell CD3 antigens) to lenalidomide plus rituximab improved the objective response rate and progression-free...
Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxane With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer
In a Chinese phase III trial (RJBC 1501) reported in the Journal of Clinical Oncology, Chen et al found that the addition of carboplatin to adjuvant epirubicin plus cyclophosphamide followed by taxane chemotherapy significantly improved disease-free survival in patients with early-stage...
HER2-Positive Gastroesophageal Cancer: Zanidatamab Plus Chemotherapy Prolongs Progression-Free Survival
Results from a new phase III study showed that in patients with HER2-positive metastatic gastroesophageal adenocarcinoma, the combination of the dual HER2-targeted bispecific antibody zanidatamab and chemotherapy, with or without the PD-1 inhibitor tislelizumab, extended progression-free survival....
Study Finds GLP-1 RAs May Influence Colorectal Cancer Mortality
Colon cancer is among the leading causes of cancer-related morbidity and mortality both in the United States and globally. Emerging evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may influence cancer mortality, and the results from a new study may add to that mounting ...
Triplet Therapy Demonstrates Superior Progression-Free Survival in First-Line dMMR/MSI-H Metastatic Colorectal Cancer
The combination regimen of FOLFOX chemotherapy (leucovorin, fluorouracil, and oxaliplatin), bevacizumab, and atezolizumab led to a statistically significant improvement in progression-free survival compared with atezolizumab monotherapy for the first-line treatment of patients with deficient...
BRAF V600E–Mutant Colorectal Cancer: First-Line Encorafenib, Cetuximab, and FOLFIRI
New results from the BREAKWATER trial show that the targeted therapy combination of encorafenib and cetuximab with the chemotherapy fluorouracil, folinic acid, and irinotecan (FOLFIRI) can reduce the size or number of tumors in patients with BRAF V600E–mutant metastatic colorectal cancer. Adding...
High Neighborhood Fast Food Expenditure and Early-Onset Colorectal Cancer
Studies show that while the overall rates of colorectal cancer are decreasing, for individuals younger than age 50, the incidence has risen by an alarming 50% since the mid-1990s. While the exact causes are unknown, poor diet and alcohol consumption are believed to be contributing factors. A study...
ASTRO Relaunches Research Foundation Under a Single, Focused Identity
The American Society of Radiation Oncology (ASTRO) has announced that they have rebranded their research foundation from the former Radiation Oncology Institute (ROI) to become Speed of Light – The ASTRO Foundation. The intent of the renamed research foundation was to bring both ASTRO and the...
Addition of Tafasitamab to Lenalidomide Plus Rituximab in Relapsed or Refractory Follicular Lymphoma
In a phase III trial (inMIND) reported in The Lancet, Sehn et al found that the addition of the CD19-targeted Fc-enhanced monoclonal antibody tafasitamab to lenalidomide plus rituximab improved progression-free survival in patients with relapsed or refractory follicular lymphoma. Study Details In...
County-Level Obesity Prevalence May Predict Obesity-Related Cancer Rates in Young Adults
The International Agency for Research on Cancer has linked obesity to increases in the development of 13 cancers, including breast, colorectal, kidney, endometrial, thyroid, pancreatic, liver, multiple myeloma, gastric cardia, meningioma, ovarian, esophageal, and gallbladder cancers. Now, a new...
A Novel Paradigm in Acute Kidney Injury: Congestive Nephropathy in RCC With IVC Thrombus
Researchers have proposed a new mechanism of acute kidney injury to account for patients with renal cell carcinoma (RCC) who have an inferior vena cava (IVC) tumor thrombus, according to findings presented at the 26th Annual Meeting of the Society of Urologic Oncology (SUO).1 By analyzing...
Deb Schrag, MD, MPH, FASCO, Elected 2027–2028 ASCO President
On December 19, 2025, ASCO announced its members had elected Deb Schrag, MD, MPH, FASCO, as President for the 2027–2028 term. Dr. Schrag will begin her term as President-Elect following the conclusion of the 2026 ASCO Annual Meeting. Dr. Schrag, a gastrointestinal medical oncologist, is the George ...
Mikkael Sekeres, MD, MS, on MDS and Exposure to Agent Orange
Mikkael Sekeres, MD, MS, Chief, Division of Hematology and Professor of Medicine at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, presents findings from a new study that connects exposure to the herbicide Agent Orange to earlier and more severe...
CD123-Targeting ADC Shows Activity in AML and BPDCN
Researchers presented new data from two ongoing studies of pivekimab sunirine, an antibody-drug conjugate targeting CD123, in treating two aggressive blood cancers at the 2025 American Society of Hematology (ASH) Annual Meeting & Exposition. In a phase Ib/II trial led by Naval Daver, MD,...
Intravesical Cretostimogene Grenadenorepvec Shows Strong High-Grade Recurrence-Free Survival in BCG-Unresponsive Papillary-Only Non–Muscle-Invasive Bladder Cancer
Intravesical cretostimogene grenadenorepvec (CG0070) monotherapy demonstrated strong high-grade recurrence-free survival rates in patients with high-risk, papillary-only, bacillus Calmette-Guérin (BCG)-unresponsive non–muscle-invasive bladder cancer, according to data presented at the 26th Annual...
Disease-Free Survival With Gemcitabine Intravesical System in BCG-Unresponsive Papillary-Only Non–Muscle-Invasive Bladder Cancer
Monotherapy with a gemcitabine intravesical system (TAR-200; Gem-iDRS) demonstrated high disease-free survival rates in patients with bacillus Calmette-Guérin (BCG)-unresponsive papillary-only high-risk non–muscle-invasive bladder cancer (NMIBC), according to data presented at the 26th Annual...
Intravesical Oncolytic Adenovirus Delivers High Complete Response Rates in BCG-Naive, High-Risk, Non–Muscle-Invasive Bladder Cancer With Carcinoma in Situ
Intravesical cretostimogene grenadenorepvec (CG0070) monotherapy demonstrated a high overall complete response rate in patients with high-risk, bacillus Calmette-Guérin (BCG)-naive non–muscle-invasive bladder cancer with carcinoma in situ, according to early results from Cohort A of the phase II...
KEYNOTE-905: Perioperative Immunotherapy Regimen Active in Cisplatin-Ineligible MIBC
A perioperative regimen of the antibody-drug conjugate enfortumab vedotin-ejfv plus the PD-1 inhibitor pembrolizumab significantly improved event-free survival, overall survival, and pathologic complete response rates compared to radical cystectomy alone in patients with muscle-invasive bladder...
Addition of Eflornithine to Lomustine in Patients With Recurrent Grade 3 Astrocytoma
As reported in the Journal of Clinical Oncology by Colman et al, the phase III STELLAR trial showed no difference in overall survival with the addition of eflornithine to lomustine in patients with recurrent grade 3 astrocytoma; however, marked progression-free survival and overall survival...
Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced NSCLC
As reported in the Journal of Clinical Oncology by Tomasini et al, findings in a cohort of the early-phase CHRYSALIS-2 trial indicate activity of amivantamab plus lazertinib in patients with atypical EGFR-mutated advanced non–small cell lung cancer (NSCLC). Study Details In the international trial, ...
Flipped Nivolumab/Ipilimumab Dosing Improves Responses, Survival, and Safety in Advanced Melanoma
The flipped dose for nivolumab at 3 mg/kg and ipilimumab at 1 mg/kg led to improved response rates and survival findings as well as lower severe immune-related toxicities compared with the standard dose of the immunotherapy combination in patients with advanced unresectable melanoma, according to...
FLIPI24: New Prognostic Model for Newly Diagnosed Follicular Lymphoma
As reported in the Journal of Clinical Oncology, Maurer et al have developed FLIPI24, a modern prognostic model for newly diagnosed follicular lymphoma. As stated by the investigators, “Although most patients with … [follicular lymphoma] can expect an indolent course, progressive lymphoma remains...
AI Models Advance Individualized Breast Cancer Recurrence Risk Assessments
Two presentations at the 2025 San Antonio Breast Cancer Symposium (SABCS) highlighted new artificial intelligence (AI) tools and systems for improving distant recurrence risk stratification among patients with early-stage breast cancer. The first tested multimodal AI models with imaging, clinical,...
Can Multimodal AI Models Predict Distant Recurrence Risk in Patients With Early Breast Cancer?
Multimodal artificial intelligence (AI) models using a combination of molecular, imaging, and clinical features improved the individual prognostic assessment of patients with early breast cancer's risk of distant recurrence, according to an analysis presented at the 2025 San Antonio Breast Cancer...
Ianalumab Plus Eltrombopag Extends Time to Treatment Failure in ITP
The addition of the investigational monoclonal antibody ianalumab to eltrombopag extended the time to treatment failure in patients with primary immune thrombocytopenia (ITP) after prior treatment with corticosteroids, according to findings from the phase III VAYHIT2 trial presented at the 2025...
Acupuncture May Improve Perceived Cognitive Difficulties in Breast Cancer Survivors
New findings from the phase II ENHANCE clinical trial indicate that both real and sham acupuncture improve breast cancer survivors’ perceived cognitive impairment more effectively than usual care alone, while real acupuncture improves objective measures of cognitive performance better than sham...
Follicular Lymphoma: Durable Remissions and Sustained Safety With Third-Line Lisocabtagene Maraleucel
Patients with relapsed or refractory follicular lymphoma treated in the third-line setting with a single infusion of the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel continued to show responses after 3 years, according to long-term follow-up results from the TRANSCEND FL...
CD40 Overexpression Emerges as a Potential Biomarker for Angioimmunoblastic T-Cell Lymphoma
Researchers at The University of Texas MD Anderson Cancer Center have identified CD40 overexpression as a potential prognostic biomarker in angioimmunoblastic T-cell lymphoma (AITL), a rare subtype of non-Hodgkin lymphoma that is difficult to diagnose and treat. The results of their study were...
Oral SERD Improves Disease-Free Survival Over Standard of Care for Patients With Early-Stage Breast Cancer
The investigational oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant improvement in invasive disease–free survival compared with the current standard-of-care endocrine therapy in patients with early-stage, hormone receptor-positive,...
HER2CLIMB-05 Study: Tucatinib Enhances Progression-Free Survival as First-Line Maintenance for HER2-Positive Metastatic Breast Cancer
The addition of the selective HER2 inhibitor tucatinib to trastuzumab and pertuzumab as first-line maintenance therapy significantly prolonged investigator-assessed progression-free survival in patients with HER2-positive metastatic breast cancer, according to findings presented at the 2025 San...
AI Tops Density in Predicting Breast Cancer Risk
An image-only artificial intelligence (AI) model for predicting the 5-year risk of breast cancer provided stronger and more precise risk stratification than breast density assessment, according to a news statement issued about a study presented at the annual meeting of the Radiological Society of...
SIO 2025: The Future of Integrative Oncology
Guest Editor’s Note: In October, the Society for Integrative Oncology (SIO) held its annual international conference in Boston. The theme was “The Future of Integrative Oncology,” with presentations and workshops focused on evidence-based integrative therapies and innovative research methodologies. ...
Experimental CAR T-Cell Therapy Shows High Efficacy and a Favorable Safety Profile in Multiple Myeloma
Updated findings from the phase II iMMagine-1 study show that anitocabtagene autoleucel (anito-cel), an investigational CAR T-cell therapy for relapsed or refractory multiple myeloma, continues to deliver high response rates with a reassuring safety profile. Researchers from The University of Texas ...
Christine M. Lovly, MD, PhD, FASCO, Named Head, Thoracic Oncology, at City of Hope
Christine M. Lovly, MD, PhD, FASCO, an expert on lung cancer with almost 2 decades of experience in clinical care, translational research, and academic leadership, will spearhead the new national thoracic oncology program at City of Hope in Duarte, California. In her new role, effective January 1, ...
Epcoritamab Added to Second-Line Lenalidomide/Rituximab Improves Responses in Follicular Lymphoma
When epcoritamab was added to lenalidomide and rituximab, response rates were significantly higher and progression-free survival was prolonged for patients with follicular lymphoma treated in the second-line setting or beyond, according to findings from the phase III EPCORE FL-1 trial presented at...
Integrating Mental Health Into Cancer Care: A Community Oncology Imperative
When Julie began chemotherapy for breast cancer, her oncologist adjusted antiemetics weekly and carefully tracked neutrophil counts. Still, no one asked about the panic attacks that kept her awake at night. She told herself this was just part of cancer. It was not until she stopped showing up for...
UICC’s World Cancer Declaration 2025–2035
The Union for International Cancer Control (UICC) published its World Cancer Declaration 2025–2035 framework on November 19, 2025.1 The declaration urges governments and policymakers to take decisive action to reduce the global burden of cancer; promote equitable access to prevention, diagnosis,...
ASCO and AI in Oncology: Rooted in Human-Centered Care
ASCO’s mission to conquer cancer through research, education, and promotion of the highest quality patient care requires curiosity, open-mindedness, and an evidence-based approach to emerging technologies. ASCO is committed to helping the oncology community understand, develop, apply, and monitor...
Jennifer Woyach, MD, on Relapsed/Refractory CLL: Next-Generation BTK Inhibitor
Jennifer Woyach, MD, of The Ohio State University Comprehensive Cancer Center, reviews phase I data on rocbrutinib, a new selective next-generation inhibitor of Bruton’s tyrosine kinase (BTK), in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and prior exposure to BTK and/or...
High Risk of Metastatic Recurrence Among Young Patients With Cancer
A new study of adolescents and young adults (AYAs) with seven common cancers reveals that nearly one in ten patients diagnosed with non-metastatic disease later develop metastatic recurrence. The information was shared in a news statement from the UC Davis Comprehensive Cancer Center. Scientists at ...
The Diagnosis I Couldn’t Deliver: An Oncologist’s Journey Between Roles
As a medical oncologist and palliative care physician, I have spent years preparing for difficult conversations. I’ve guided patients and families through the uncertainty of cancer, helped them navigate complex decisions, and sought meaning amid shifting prognoses. As an academic, I teach future...
Mount Sinai Tisch Cancer Center Receives Comprehensive Cancer Center Designation and Funding from National Cancer Institute
The Mount Sinai Tisch Cancer Center (TCC) has been named a Comprehensive Cancer Center by the National Cancer Institute (NCI), the highest designation awarded to cancer centers in the United States. This recognition places Mount Sinai among the top one percent of cancer centers nationwide and...
